Scarica l'app Stockscreener
19.95
6.82%
-1.46
Dopo l'orario di chiusura:
19.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Homocystinuria Market Growth, Trends & Forecast 2025 | Leading - openPR.com
Travere therapeutics CEO sells $398k in stock By Investing.com - Investing.com Nigeria
Travere therapeutics CEO sells $398k in stock - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 - Investing.com Australia
Travere Therapeutics Executives Sell Shares - TradingView
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
(TVTX) Technical Data - news.stocktradersdaily.com
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report - Yahoo Finance
Travere Therapeutics (TVTX) Sees Promising Growth with FILSPARI - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Travere Therapeutics (TVTX) Rating and Price Target Update by We - GuruFocus
Travere Therapeutics (TVTX) Price Target Raised by Stifel | TVTX Stock News - GuruFocus
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst ... - Yahoo
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst Challenges - GuruFocus
Travere: Q1 Earnings Snapshot - Norwalk Hour
Travere Therapeutics Reports Strong Q1 2025 Financial Results - TipRanks
Travere Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Travere Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) - Seeking Alpha
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast By Investing.com - Investing.com South Africa
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics Reports First Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast - Investing.com
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 - GuruFocus
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36 - marketscreener.com
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filsp - GuruFocus
European Commission Grants Standard Approval for Travere's Filsp - GuruFocus
Travere, CSL get standard EU nod for kidney drug (TVTX:NASDAQ) - Seeking Alpha
Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy - marketscreener.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval - GuruFocus
How to interpret Travere Therapeutics Inc (TVTX)’s stock chart patterns - uspostnews.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy | TVTX Stock News - GuruFocus
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy - Business Wire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - The Manila Times
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | CSLLY Stock News - GuruFocus
Breakthrough: FILSPARI Secures Standard EU Approval as First DEARA Therapy for IgA Nephropathy - Stock Titan
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Travere Therapeutics Inc [NASDAQ: TVTX] Sees Increase in Stock Value - knoxdaily.com
Cantor Fitzgerald Reaffirms “Overweight” Rating for Travere Therapeutics (NASDAQ:TVTX) - Defense World
Travere Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus
Travere Therapeutics to Report First Quarter 2025 Financial Results - Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts - Benzinga
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Cantor Fitzgerald maintains Overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Commit To Purchase Travere Therapeutics At $15, Earn 22.8% Annualized Using Options - Nasdaq
Travere Therapeutics Inc (TVTX)’s stock price range in the last year - uspostnews.com
Travere Therapeutics Provides Corporate Update and 2025 Outlook - ADVFN
6.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):